Back
 PP  Vol.4 No.2 , April 2013
Population Pharmacokinetics of Methotrexate in Egyptian Children with Lymphoblastic Leukemia
Abstract: Background: Individualization of high dose regimen of methotrexate (MTX) in pediatric patients with acute lymphoblastic leukemia based on pharmacokinetic (PK) parameters can help in optimization of the dose and better control of the disease. Building up of a pharmacokinetic model can help dose optimization. Objectives: A NONMEM based population (POP) PK model has been subsequently developed to evaluate the effect of demographics as covariates to address variability in pharmacokinetics of MTX. Method: Forty one patients (24 males & 17 females) with ranges of age, body weight and height of 3 - 15 years, 13 - 54 kg and 100 - 177 cm respectively and diagnosed as acute lymphoblastic leukemia (ALL) were involved in the study. MTX was administered as i.v. infusion at a dose of 2 gm/m2 over a period of two hour and its plasma concentrations were determined primarily at 24 hr post-dose to be utilized in the building-up of PK model.The initial/prior estimates of volumes of central (V1) and peripheral compartments (V2) and clearance (CL) and inter-compartmental clearance (Q2) for MTX were extracted from literature. The inter-subject variability was estimated for V1 & CL. The influence of different covariates on model performance and parameter estimates was assessed by evaluating the difference in objective function value. The final POP PK model was validated by bootstrap re-sampling procedures (1000 runs) and the 95% confidence intervals for the estimates were calculated. Results: The POP estimates for CL, V1 and V2 were 2.18 L/h, 5.74 L and 11.2 L respectively. The inter-individual variability for the CL and V1 was 23% and 30% respectively. The covariates analysis showed effect of body surface area and sex on the CL and weight on V1. Conclusions: The POP-PK model developed adequately defines the population PK of MTX in pediatric patients with lymphoblastic leukemia. The model showed effect of body surface area and sex on clearance and weight on volume of distribution of the MTX. Further studies are required on larger number of patients with enrichment of samples for MTX concentrations. The developed PK model should be also investigated in correlation with the genotyping style of different MTX transporters that may affect MTX PK parameters.
Cite this paper: E. Desoky, M. Ghazal, R. Singh, O. Abdelhamid and H. Derendorf, "Population Pharmacokinetics of Methotrexate in Egyptian Children with Lymphoblastic Leukemia," Pharmacology & Pharmacy, Vol. 4 No. 2, 2013, pp. 139-145. doi: 10.4236/pp.2013.42020.
References

[1]   A. M. Linabery and J. A. Ross, “Trends in Childhood Cancer Incidence in the US (1992-2004),” Cancer, Vol. 112, No. 2, 2008, pp. 416-432. doi:10.1002/cncr.23169

[2]   N. Gokbuget and D. Hoelzer, “High-Dose Methotrexate in the Treatment of Adult Acute Lymphoblastic Leukemia,” Annals of Hematology, Vol. 72, No. 4, 1996, pp. 194-201. doi:10.1007/s002770050160

[3]   C. Rask, F. Albertioni, S. M. Bentzen, H. Schroeder and C. Peterson, “Clinical and Pharmacokinetic Risk Factors for High-Dose Methotrexate-Induced Toxicity in Children with Acute Lymphoblastic Leukemia—A Logistic Regression Analysis,” Acta Oncologica, Vol. 37, No. 3, 1998, pp. 277-284. doi:10.1080/028418698429586

[4]   H. Seidel, R. Nygaard, P. J. Moe, G. Jacobsen, B. Lindqvist and L. Slordal, “On the Prognostic Value of Systemic Methotrexate Clearance in Childhood Acute Lymphocytic Leukemia,” Leukemia Research, Vol. 21, No. 5, 1997, pp. 429-434. doi:10.1016/S0145-2126(96)00127-0

[5]   J. D. Borsi and P. J. Moe, “Systemic Clearance of Methotrexate in the Prognosis of Acute Lymphoblastic Leukemia in Children,” Cancer, Vol. 60, No. 12, 1987, pp. 3020-3024. doi:10.1002/1097-0142(19871215)60:12<3020::AID-CNCR2820601227>3.0.CO;2-0

[6]   W. E. Evans, M. V. Relling, J. H. Rodman, W. R. Crom, J. M. Boyett and C-H. Pui, “Conventional Compared with Individualized Chemotherapy for Childhood Acute Lymphoblastic Leukemia,” The New England Journal of Medicine, Vol. 338, No. 8, 1998, pp. 499-505. doi:10.1056/NEJM199802193380803

[7]   M. Schrappe, A. Reiter, W. D. Ludwig, J. Harbott, M. Zimmermann, W. Hiddemann, C. Niemeyer, G. Henze, A. Feldges, F. Zintl, B. Kornhuber, J. Ritter, K. Welte, H. Gadner and H. Riehm, “Improved Outcome in Childhood Acute Lymphoblastic Leukemia Despite Reduced Use of Anthracyclines and Cranial Radiotherapy: Results of Trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group,” Blood, Vol. 95, No. 11, 2000, pp. 3310-3322.

[8]   S. L. Beal and L. B. Sheiner, “NONMEM User Guides (I-VIII),” University of California at San Francisco, San Francisco, 1998.

[9]   I. Grabner, B. Fraganel, V. Dolzan, A. Mrhar and J. Jazbec, “Population Pharmacokinetics of Methotrexate in Children with Lymphoid Malignancy,” The Annual Meeting of the Population Approach Group in Europe, 2007, p. 16. www.page-meeting.org/?abstract=1199

[10]   C. Zhang, S. Zhai, L. Yang, H. Wu, J. Zhang and X. Ke, “Population Pharmacokinetic Study of Methotrexate in Children with Acute Lymphoblastic Leukemia,” International Journal of Clinical Pharmacology and Therapeutics, Vol. 48, No. 1, 2010, pp. 11-21.

[11]   B. C. Widemann and P. C. Adamson, “Understanding and Managing Methotrexate Nephrotoxicity,” The Oncologist, Vol. 11, No. 6, 2006, pp. 694-703. doi:10.1634/theoncologist.11-6-694

[12]   C. Ritzmo, F. Albertioni, K. Cosic, S. Soderhall and S. Eksborg, “Therapeutic Drug Monitoring of Methotrexate on the Pediatric Oncology Ward: Can Blood Sampling from Central Venous Accesses Substitute for Capillary Finger Punctures?” Therapeutic Drug Monitoring, Vol. 29, No. 4, 2007, pp. 447-451. doi:10.1097/FTD.0b013e318063e5e5

[13]   F. Odoul, C. Le Guellec, J. P. Lamagnère, D. Breilh, M. C. Saux, G. Paintaud and E. Autret-Leca, “Prediction of Methotrexate Elimination after High Dose Infusion in Children with Acute Lymphoblastic Leukaemia Using a Population Pharmacokinetic Aapproach,” Fundamental and Clinical Pharmacology, Vol. 13, No. 5, 1999, pp. 595-604. doi:10.1111/j.1472-8206.1999.tb00366.x

[14]   J. Chládková, J. Hak, J. Martínková and J. Chládek, “High-Dose Methotrexate in Children with Acute Lymphoblastic Leukemia: 7-Hydroxymethotrexate Systemic Exposure and Urinary Concentrations at the Steady State Correlate Well with Those of Methotrexate,” Arzneimittel-Forschung, Vol. 60, No. 12, 2010, pp. 769-775.

[15]   T. D. Buitenkamp , R. A. Mathot , V. de Haas, R. Pieters and C. M. Zwaan, “Methotrexate-Induced Side Effects Are Not Due to Differences in Pharmacokinetics in Children with Down Syndrome and Acute Lymphoblastic Leukemia,” Haematologica, Vol. 95, No. 7, 2010, pp. 1106-1113. doi:10.3324/haematol.2009.019778

[16]   N. Martelli, O. Mathieu, G. Margueritte, M. C. Bozonnat, J. P. Daures, F. Bressolle, D. Hillaire-Buys and H. Peyrière, “Methotrexate Pharmacokinetics in Childhood Acute Lymphoblastic Leukaemia: A Prognostic Value?” Journal of Clinical Pharmacy and Therapeutics, Vol. 36, No. 2, 2011, pp. 237-245. doi:10.1111/j.1365-2710.2010.01179.x

[17]   B. F. Kotnik, I. Grabnar, P. B. Grabar, V. Dolzan and J. Jazbec, “Association of Genetic Polymorphism in the Folate Metabolic Pathway with Methotrexate Pharmacokinetics and Toxicity in Childhood Acute Lymphoblastic Leukaemia and Malignant Lymphoma,” European Journal of Clinical Pharmacology, Vol. 67, No. 10, 2011, pp. 993-1006. doi:10.1007/s00228-011-1046-z

[18]   P. Jonsson , T. Skarby, J. Heldrup, H. Schroder and P. Hoglund, “High Dose Methotrexate Treatment in Children with Acute Lymphoblastic Leukaemia May Be Optimised by a Weight-Based Dose Calculation,” Pediatric Blood & Cancer, Vol. 57, No. 1, 2011, pp. 41-46. doi:10.1002/pbc.22999

[19]   H. Sun, E. O. Fadiran, C. D. Jones, L. Lesko, S. M. Huang, K. Higgins, C. Hu, S. Machado, S. Maldonado, R. Williams, M. Hossain and E. I. Ette, “Population Pharmacokinetics. A Regulatory Perspective,” Clinical Pharmacokinetics, Vol. 37, No. 1, 1999, pp. 41-58. doi:10.2165/00003088-199937010-00003

[20]   E. S. EL Desoky, N. V. Nagaraja and H. Derendorf, “Population Pharmacokinetics of Digoxin in Egyptian Pediatric Patients: Impact of One Data Point Utilization,” American Journal of Therapeutics, Vol. 9, No. 6, 2002, pp. 492-498.

[21]   N. Simon , A. Marsot, E. Villard, S. Choquet, H. X. Khe, N. Zahr, P. Lechat, V. Leblond and J. S. Hulot, “Impact of ABCC2 Polymorphisms on High-Dose Methotrexate Pharmacokinetics in Patients with Lymphoid Malignancy,” The Pharmacogenomics Journal, 2012 (online). doi:10.1038/tpj.2012.37

[22]   L. R. Trevino, N. Shimasaki, W. Yang, J. C. Panetta, C. Cheng, D. Pei, D. Chan, A. Sparreboom, K. M. Giacomini, C. H. Pui, W. E. Evans and M. V. Relling, “Germline Genetic Variation in an Organic Anion Transporter Polypeptide Associated with Methotrexate Pharmacokinetics and Clinical Effects,” Jurnal of Clinical Oncology, Vol. 27, No. 35, 2009, pp. 5972-5978. doi:10.1200/JCO.2008.20.4156

[23]   L. B. Ramsey, G. H. Bruun, W. Yang, L. R. Trevino, S. Vattathil, P. Scheet, C. Cheng, G. L. Rosner, K. M. Giacomini, Y. Fan, A. Sparreboom, T. S. Mikkelsen, T. J. Corydon, C. H. Pui, W. E. Evans and M. V. Relling, “Rare versus Common Variants in Pharmacogenetics: SLCO1B1 Variation and Methotrexate Disposition,” Genome Research, Vol. 22, No. 1, 2012, pp. 1-8. doi:10.1101/gr.129668.111

 
 
Top